Author:
Naing Aung,Fu Siqing,Zinner Ralph G.,Wheler Jennifer J.,Hong David S.,Arakawa Kazuhito,Falchook Gerald S.,Kurzrock Razelle
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference17 articles.
1. Álvarez P, Marchal JA, Boulaiz H et al (2012) 5-fluorouracil derivatives: a patent review. Expert Opin Ther Pat 22(2):107–123, Epub 2012 Feb 14
2. Hattori H, Tanaka M, Fukushima M et al (1996) Nucleosides and nucleotides. 1-(3′-C-Ethynyl-ß-D-ribo-pentofuranosyl)-cytosine, 1-(3′-C-Ethynyl-ß-D-ribopentofuranosyl)uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity. J Med Chem 39(25):5005–5011
3. Tabata S, Tanaka M, Matsuda A et al (1996) Antitumor effect of a novel multifunctional antitumor nucleoside, 3’-ethynylcytidine, on human cancers. Oncol Rep 3(6):1029–1034
4. Fukushima M (1998) The new antitumor ribonucleoside 3’-C-ethynylcytidine: its antitumor effects and mechanism of action. Purine Pyrimidine Metab 22(2):189–199
5. Kazuno H, Shimamoto Y, Tsujimoto H et al (2007) Mechanism of action of a new antitumor ribonucleoside, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), differs from that of 5-fluorouracil. Oncol Rep 17(6):1453–1460
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献